October 29, 2015 at 6:00 PM
1050 Connecticut Ave NW
click for directions »
* This program is sponsored by Alnylam Pharmaceuticals.
The Association of Black Cardiologists invites you to attend a dinner program titled “TTR-amyloidosis — from Epidemiology to Diagnosis to Current Research on Novel Therapies.” The program will include presentations by well-known heart failure specialists and discussions of current Phase 2 and Phase 3 research trials and treatment options for Transthyretin (TTR)-mediated amyloidosis (ATTR).
Dan Judge, MD
Daniel P. Judge is associate professor of medicine in Cardiology at Johns Hopkins University. Dr. Judge specializes in inherited diseases of the heart, including heart valve disorders, cardiomyopathy, amyloidosis, and Marfan syndrome. He founded the JHU Center for Inherited Heart Disease at the Johns Hopkins School of Medicine and currently serves as its medical director and is active in patient care, research and teaching.
Dr. Judge holds patents related to medical methods and procedures and is the author of at least 100 peer-reviewed articles. He is board-certified in Advanced Heart Failure & Transplant Cardiology, and directs the post-doctoral fellowship in this subspecialty.
Jonathan Plehn, MD
Jonathan Plehn is Vice President in Cardiovascular Medicine at Covance, Inc., and Clinical Professor of Medicine at Drexel University School of Medicine. Dr. Plehn earned his Doctorate in Medicine from New York University School of Medicine and completed an internship and residency at Montefiore Hospital, University of Pittsburgh before completing his cardiology fellowship at Rush-Presbyterian-St. Luke's Medical Center in Chicago with further training at Boston University School of Public Health. Dr. Plehn has a wide range of therapeutic trial experience in the areas of lipid therapy, congestive heart failure and the design and management of cardiovascular outcomes trials.